Analyzing Curaleaf (OTCMKTS:CURLF) and Orchestra BioMed (NASDAQ:OBIO)

Curaleaf (OTCMKTS:CURLF) and Orchestra BioMed (NASDAQ:OBIO) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Curaleaf and Orchestra BioMed, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curaleaf	0	0	2	3	3.60
Orchestra BioMed	1	0	6	0	2.71

Orchestra BioMed has a consensus target price of $13.17, suggesting a potential upside of 115.71%. Given Orchestra BioMed’s higher probable upside, analysts clearly believe Orchestra BioMed is more favorable than Curaleaf.

Profitability

This table compares Curaleaf and Orchestra BioMed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Curaleaf	-2.62%	-0.88%	-0.26%
Orchestra BioMed	-184.60%	-149.61%	-54.15%

Volatility & Risk

Curaleaf has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, Orchestra BioMed has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.

Institutional & Insider Ownership

0.0% of Curaleaf shares are held by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Curaleaf and Orchestra BioMed”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curaleaf	$1.27 billion	1.84	-$231.07 million	($0.13)	-76.92
Orchestra BioMed	$31.98 million	11.47	-$52.70 million	($0.85)	-7.18

Orchestra BioMed has lower revenue, but higher earnings than Curaleaf. Curaleaf is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Summary

Curaleaf beats Orchestra BioMed on 8 of the 15 factors compared between the two stocks.

About Curaleaf

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.